Product Overview
[Drug Name]
Generic Name: Candesartan Cilexetil Tablets
Trade Name: Vilya Candesartan Cilexetil Tablets, 4mg x 14 Tablets
Pinyin Code: KanDishaTanZhiPian
[Main Ingredients]
The main ingredient of this product is candesartan cilexetil.
[Appearance]
This product is white tablets.
[Indications/Main Functions]
For the treatment of essential hypertension. This product can be used alone or in combination with other antihypertensive drugs.
[Specifications]
4mg x 14 tablets (Vilya)
[Dosage and Administration]
Oral. Generally, adults take 4-8mg once daily. The dose can be increased to 12mg if necessary.
[Adverse Reactions]
Serious adverse reactions (incidence unknown): () Angioedema: Angioedema, which may occur on the face, lips, tongue, pharynx, or larynx, should be carefully observed. If any abnormality is observed, discontinue use and administer appropriate treatment. (2) Syncope and loss of consciousness: Excessive blood pressure reduction may cause syncope and temporary loss of consciousness. In this case, the drug should be stopped and appropriate treatment should be carried out. In particular, patients undergoing hemodialysis, patients undergoing strict salt restriction therapy, and patients who have recently started taking diuretic antihypertensive drugs may experience a rapid drop in blood pressure. Therefore, these patients should start treatment with this drug at a lower dose. If it is necessary to increase the dose, the patient's condition should be closely observed and the increase should be slow. (3) Acute renal failure: Acute renal failure may occur. The patient's condition should be closely observed. If abnormalities are found, the drug should be stopped and appropriate treatment should be carried out. (4) Patients with hyperkalemia: In view of the possibility of hyperkalemia, the patient's condition should be closely observed. If abnormalities are found, the medication should be stopped and appropriate treatment should be carried out. (1) Liver function deterioration or jaundice: In view of the possibility of liver dysfunction or jaundice with increased AST(GON), ACT(GPT), Y-GTP, etc., the patient's condition should be closely observed. If abnormalities are found, the medication should be stopped and appropriate treatment should be carried out. (6) Agranulocytosis: Agranulocytosis may occur, and the patient's condition should be closely observed. If abnormalities are found, the medication should be stopped and appropriate treatment should be carried out. (7) Rhabdomyolysis: Symptoms such as myalgia, weakness, increased CK, and myosin in the blood and urine may occur. If the above conditions occur, the medication should be stopped and appropriate treatment should be carried out. (8) Interstitial pneumonia: There may be Interstitial pneumonia with fever, cough, dyspnea, or abnormal chest X-ray findings should occur. If these symptoms occur, discontinue medication and institute appropriate treatment, such as corticosteroids.
[Contraindications]
1. Patients with a history of allergic reactions to any of the ingredients in this preparation. 2. Pregnant or potentially pregnant women. 3. Patients with severe hepatic or renal impairment or cholestasis.
[Drug Interactions]
Caution with combined use (caution should be exercised when using combined medications). This product has no significant interactions with glyburide, nimodipine, digoxin, warfarin, or hydrochlorothiazide. There are also no significant interactions with oral contraceptives in healthy subjects.
[Precautions]
1. Use with caution (for the following patients: (2) Patients with bilateral or unilateral renal artery (see 2 Important basic precautions. (3) Patients with liver dysfunction (it may worsen liver function. In addition, it is speculated that the clearance rate of the active metabolite candesartan is reduced, so it should be taken from a small dose and used with caution). (4) Patients with severe renal dysfunction (due to excessive blood pressure reduction, it may worsen renal function, so it should be taken once a day, starting from 2 mg, and used with caution). (5) Patients with a history of drug allergy. (6) Elderly patients). (7 Kidney transplantation: There is no experience with this product for patients who have recently undergone kidney transplantation. (8) Large Arterial and left atrioventricular valve stenosis (obstructive cardiomyopathy): Patients using other vasodilators, patients with hemodynamically relevant aortic or left atrioventricular valve stenosis or obstructive cardiomyopathy should use this drug with caution. (9) Mild to moderate adrenocorticoid hyperplasia: Patients with mild to moderate adrenocorticoid hyperplasia usually do not respond to antihypertensive drugs that inhibit the renin-angiotensin and aldosterone systems, so it is not recommended to take this drug. 2. Important basic precautions () Patients with bilateral or unilateral renal artery stenosis may increase the risk of renal function when taking drugs for the renin-angiotensin-aldosterone system due to the decrease in renal blood flow and filtration pressure, unless it is considered necessary for treatment. (⑵) As it may aggravate hyperkalemia, patients with hyperkalemia should avoid taking this drug unless it is considered necessary for treatment. In addition, patients with uncontrolled diabetes and renal dysfunction should pay close attention to their blood potassium levels because these patients are prone to developing hyperkalemia. () Since taking this preparation may sometimes cause a sharp drop in blood pressure, especially for the following patients, it should be started with a small dose. When increasing the dose, the patient's condition should be carefully observed and the process should be slow. A. Patients undergoing hemodialysis. B. Patients undergoing strict salt restriction therapy. C. Patients taking diuretic antihypertensive drugs (especially those who have recently started taking diuretic antihypertensive drugs). (4) Due to the antihypertensive effect, sometimes If you experience dizziness or staggering, be careful when working at height or driving a vehicle. (5) It is best to stop taking the drug 24 hours before surgery. (6) When taking the drug: The drug packaged in the PTP should be taken after it is removed from the PTP sheet (there have been reports of accidental ingestion of the hard, sharp corners of the PTP sheet piercing the esophageal mucosa, leading to perforation and complications such as mediastinitis).
[Drug Use in Children]
The safety of the drug for children has not been determined (no experience).
[Drug Use in Elderly Patients]
It is generally believed that blood pressure should not be excessively lowered in the elderly (it may cause cerebral infarction, etc.). It should be taken with caution while the patient is under observation. For elderly people with normal liver and kidney function, the starting dose is 4 mg. For patients with renal or For patients with hepatic insufficiency, the recommended starting dose is 2 mg, and the dose should be increased or decreased based on the patient's condition.
[Overdose]
According to pharmacological studies, overdose primarily manifests as symptomatic hypotension and dizziness. If symptomatic hypotension occurs, symptomatic treatment and vital signs must be monitored. The patient should be placed in a supine position with the feet elevated and the head down. If necessary, isotonic saline should be injected to increase plasma volume. If the above measures fail to correct the condition, sympathomimetic drugs can be administered.
[Pharmacology and Toxicology]
Candesartan cilexetil is rapidly hydrolyzed in vivo to its active metabolite, candesartan. Candesartan is a selective angiotensin-1 (AT1) receptor antagonist that binds to AT1 receptors on vascular smooth muscle, inhibiting vascular tension. Candesartan has a vasoconstrictive effect on adrenal aldosterone, thereby reducing peripheral vascular resistance. It is also believed that candesartan may exert a certain antihypertensive effect by inhibiting adrenal aldosterone secretion. Candesartan does not inhibit kininase π and does not affect bradykinin degradation. Experiments conducted on hypertensive patients have shown that repeated use of this product can lead to increases in plasma renin activity, angiotensin 1 concentrations, and angiotensin II concentrations. Continuous daily administration of 2-8 mg of this product can reduce systolic and diastolic blood pressure, left ventricular myocardial weight, and peripheral vascular resistance, while having no significant effect on cardiac output, ejection fraction, renal vascular resistance, renal blood flow, or glomerular filtration rate. It has no effect on cerebral blood flow in patients with primary hypertension and cerebrovascular disorders.
